Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study

Mavratzas, A.; Baek, S.; Gerber, B.; Schmidt, M.; Moebus, V; Foerster, F.; Grischke, E. M.; Fasching, P.; Strumberg, D.; Solomayer, E.; Klare, P.; Windemuth-Kieselbach, C.; Hartmann, S.; Schneeweiss, A.; Marine, F.

dc.contributor.author	Grischke, Eva-Maria
dc.date.accessioned	2020-04-14T06:34:33Z
dc.date.available	2020-04-14T06:34:33Z
dc.date.issued	2019
dc.identifier.issn	1532-3080
dc.identifier.uri	http://hdl.handle.net/10900/99556
dc.language.iso	en	de_DE
dc.publisher	Churchill Livingstone	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.breast.2019.02.002	de_DE
dc.subject.ddc	610	de_DE
dc.title	Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190926111821_01280
utue.publikation.seiten	22-28	de_DE
utue.personen.roh	Mavratzas, A.
utue.personen.roh	Baek, S.
utue.personen.roh	Gerber, B.
utue.personen.roh	Schmidt, M.
utue.personen.roh	Moebus, V
utue.personen.roh	Foerster, F.
utue.personen.roh	Grischke, E. M.
utue.personen.roh	Fasching, P.
utue.personen.roh	Strumberg, D.
utue.personen.roh	Solomayer, E.
utue.personen.roh	Klare, P.
utue.personen.roh	Windemuth-Kieselbach, C.
utue.personen.roh	Hartmann, S.
utue.personen.roh	Schneeweiss, A.
utue.personen.roh	Marine, F.
dcterms.isPartOf.ZSTitelID	Breast	de_DE
dcterms.isPartOf.ZS-Volume	45	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE